Trevi Therapeutics Inc - Asset Resilience Ratio
Trevi Therapeutics Inc (TRVI) has an Asset Resilience Ratio of 69.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Trevi Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Trevi Therapeutics Inc's Asset Resilience Ratio has changed over time. See what is Trevi Therapeutics Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Trevi Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Trevi Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $138.06 Million | 69.25% |
| Total Liquid Assets | $138.06 Million | 69.25% |
Asset Resilience Insights
- Very High Liquidity: Trevi Therapeutics Inc maintains exceptional liquid asset reserves at 69.25% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Trevi Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Trevi Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.64% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
Annual Asset Resilience Ratio for Trevi Therapeutics Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Trevi Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 66.30% | $73.53 Million | $110.90 Million | +9.73pp |
| 2023-12-31 | 56.57% | $50.57 Million | $89.40 Million | -31.16pp |
| 2022-12-31 | 87.73% | $107.92 Million | $123.02 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $38.48 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $20.49 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $22.23 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $8.41 Million | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is … Read more